Please login to the form below

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to recruit another 100 patients to add

Latest news

Halozyme halts pancreatic cancer trial

Halozyme halts pancreatic cancer trial. The biopharma company is investigating PEGPH20’ s links to blood clot. ... Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the candidate's safety.
Baxter re-files HyQvia for immunodeficiency in US

HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche wins EU approval for injectable Herceptin

Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Roche's Perjeta backed in EU for breast cancer

Roche is also developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of trastuzumab - partnered with Halozyme Therapeutics - that is also in the latter stages of development.
Roche's T-DM1 activity in breast cancer "outstanding"

Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Pharma deals in June 2015

Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Deal Watch table for December 2014

Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Pharma deals during December 2014

Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Amgen veteran Kurt Gustafson joins Spectrum as CFO

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home based, Principal Medical Writer, Medical Communications: Excellent package

Editorial Director – Medical Education (MedComms): Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager: Competitive salary commensurate with experience

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Manager: £40, 000 - £45, 000 benefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director – Healthcare Advertising - London: Neg

Client Services Director - Med Comms: Great salary and bebefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Subscribe to our email news alerts

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....